相关实验视频

Updated: Jan 10, 2026

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

在ICH M13B立即释放固体口服剂型框架中探索额外强度的生物豁免前景:机遇和挑战

Rajkumar Boddu¹, Arvind Rachapally¹, Mohammed Shareef Khan¹

¹Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd, Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, Telangana, 500090, India.

Therapeutic innovation & regulatory science

|November 25, 2025

概括

国际协调理事会 (ICH) M13B指南草案协调了额外的仿制药强度的生物豁免标准. 本综述将ICH M13B与EMA和USFDA的要求进行比较,强调进入市场的挑战和好处.

科学领域:

制药科学制药科学
监管事务监管事务
药物开发药物开发

背景情况:

通用药物开发需要证明生物等价性才能进入市场.
对额外优势的生物豁免简化了监管过程.
欧洲药物管理局 (EMA) 和美国食品和药物管理局 (USFDA) 的现有指导方针对生物豁免有特定的标准.

研究的目的:

审查和比较ICH M13B指南草案中概述的生物豁免标准与EMA和USFDA的标准.
突出与ICH M13B指导额外强度生物放弃器相关的优势和挑战.
为ICH M13B.中的修订解散相似性评估的理由,风险和好处提供见解.

主要方法:

对监管指导文件进行比较分析 (ICH M13B草案,EMA,USFDA).
对药物动力学线性,配方比例性和溶解相似性标准的审查.
评估拟议变更在解散相似性评估中的影响.

主要成果:

ICH M13B指南引入了对额外强度的协调生物豁免要求.
解散相似性评估的重大变化既带来优势,也带来挑战.
对比揭示了ICH M13B,EMA和USFDA要求之间的差异和相似之处.

结论:

ICH M13B指南提供了对额外强度生物放弃的协调方法.
了解溶解相似性评估的细微差别对于监管成功至关重要.
本审查为导航额外强度生物豁免的监管提交提供了路线图.

关键词:

增加了额外的强度.生物等价性生物等价性生物废弃物生物废弃物解散解散解散解散配方配方是一种配方.在ICHM13B中.

更多相关视频

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

相关概念视频

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...

Drug Product Performance: In Vitro–In Vivo Correlation

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...